stockportfolio.pro
Stocks / ENOV vs MLTX
ENOV vs MLTX
Enovis Corporation and MoonLake Immunotherapeutics side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Enovis Corporation (ENOV) | MoonLake Immunotherapeutics (MLTX) | |
|---|---|---|
| Market cap | $1.3B | $1.3B |
| Revenue (latest FY) | $2.25B | $0 |
| Net income (latest FY) | $-1.18B | $-227.32M |
| Revenue growth (5y CAGR) | 14.9% | — |
| Net margin | -52.7% | — |
| Return on equity | -79.5% | -74.7% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 5 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ENOV — free Open MLTX — freeFrequently asked questions
Which is bigger, ENOV or MLTX?
MoonLake Immunotherapeutics is larger by market capitalization — $1.3B versus $1.3B.
Which grows faster, ENOV or MLTX?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.